Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Despite constituting 12.7% of breast cancer (BC) cases, TNBC comprises 40% of BC mortalities with a three-fold increase in ea...
Julie Liu, Mario Morales Martinez, Eduardo Mauricio Gonzalez et al.· Cancer Epidemiology, Biomark...· 0 citations
Aging drives chronic disease in part through senescent cells, including macrophages, which fuel inflammation. Senescent macrophages are functionally heterogeneous: canonical p16-high macrophages promote tumorigenesis or, in other contexts, disease tolerance, whereas we previously identified a distinct p21-high, p16-low...
Grasiela Torres, Ivan A. Salladay-Perez, Christina Y. Deng et al.· bioRxiv· 0 citations
A novel treatment based on the biguanide metformin structure, termed JD006, which significantly inhibits TNBC cell growth in vitro and in vivo in a dose-dependent manner and at lower doses than its parental metformin, provides a strong preclinical rationale for combining next-generation biguanides with CDK4/6 inhibitor...
Julie Liu, Mario Morales Martinez, Eduardo Mauricio Gonzalez et al.· Clinical Cancer Research· 0 citations
A previously unrecognized chromatin-to-metabolism axis connecting gain-of-function ASXL1 truncation to mitochondrial pyruvate transport is defined, identifying MPC as a central mediator of epigenetic-metabolic crosstalk in both a rare developmental syndrome and ASXL1-mutant myeloid malignancy.
Isabella Lin, Michael Sigfrid S. Reyes, A. Krall et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
